The way the world defines obesity has been in need of an overhaul, according to some experts, and it could be coming soon thanks to a new set of standards.

New recommendations on how to define obesity would reduce the emphasis on body mass index and take into account health problems from extra weight and other measurements.

A new study finds that three quarters of American adults and half of adolescents are too heavy. That's making more of us sick and creating enormous health care costs.

A front-of-package food label would be a great educational tool. The Trump administration should keep it.

Adults with overweight or obesity and type 2 diabetes who are ... new research led by the University of ... Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy ...

A commission proposed a new definition of obesity focused on how excess fat affects the body, rather than assessing body mass index, that could change clinical care.

A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications. Experts break down the findings.

The study revealed that weight-loss drugs significantly benefit neurological and behavioral health, including decreased risks of addiction.

As demand for weight-loss injections sold under brand names such as Ozempic and Wegovy continues to soar, a study has uncovered neurological and behavioral health benefits amid risks for pancreatitis and kidney disease.

Ziyad Al-Aly, Washington University in St. Louis (THE CONVERSATION ... have become household names and key tools in the fight against obesity: 1 in 8 American adults say they have used a GLP-1 drug, and forecasts show that by 2030, 1 in 10 Americans ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s tirzepati | An observational study from Washington University in St.

Weight loss jabs, such as Wegovy, have been linked to reduced risk of dementia and seizures – but increased risk of other disorders.